Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00004215 · ClinicalTrials.gov registry record · Phase 2
Leridistim Compared With Filgrastim in Treating Older Patients With Acute Myeloid Leukemia
A Phase 2 study, sponsored by Memorial Sloan Kettering Cancer Center.
- Completed
- Registry status
- Phase 2
- Development phase
NCT00004215: Completed Phase 2 study, sponsored by Memorial Sloan Kettering Cancer Center.
NCT00004215 is a Phase 2 study that has completed, run by Memorial Sloan Kettering Cancer Center. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00004215, a Phase 2 study, has completed, sponsored by Memorial Sloan Kettering Cancer Center.
- COMPLETED
- Registry status
- Phase 2
- Development phase
Study Summary
RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Colony-stimulating factors such as leridistim and filgrastim increase the number of immune cells found in bone marrow or peripheral blood and may help a person's immune system recover from the side effects of chemotherapy. PURPOSE: Randomized phase II trial to compare the effectiveness of leridistim with that of filgrastim to reduce side effects in older patients who are receiving cytarabine and daunorubicin for acute myeloid leukemia.
Interventions
- BIOLOGICAL filgrastim
- DRUG cytarabine
- DRUG daunorubicin hydrochloride
- BIOLOGICAL leridistim
Trial Details
| Field | Value |
|---|---|
| Start Date | 1999-08 |
| Est. Completion | 2000-08 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00004215
The ClinicalTrials.gov registry entry for NCT00004215 describes a study currently listed as completed, categorized as Phase 2. An enrollment target was not published in the registry record, which is common for early-stage or observational entries. The listed sponsor is Memorial Sloan Kettering Cancer Center, which has 1,884 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which filgrastim is the first listed.
NCT00004215 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00004215 about?
NCT00004215 is a clinical study titled "Leridistim Compared With Filgrastim in Treating Older Patients With Acute Myeloid Leukemia". RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Colony-stimulating factors such as leridistim and filgrastim increase the number of immune cells found in bone marrow or peripheral blood and may help a person's immune system rec...
What is the current status of trial NCT00004215?
This trial is currently completed. It is a Phase 2 study. The study started on 1999-08. Estimated completion is 2000-08.
What interventions are being tested in trial NCT00004215?
The interventions under investigation include: filgrastim (BIOLOGICAL), cytarabine (DRUG), daunorubicin hydrochloride (DRUG), leridistim (BIOLOGICAL).
Who is sponsoring clinical trial NCT00004215?
This trial is sponsored by Memorial Sloan Kettering Cancer Center, which has 1,884 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.